Welcome to our dedicated page for Moderna news (Ticker: MRNA), a resource for investors and traders seeking the latest updates and insights on Moderna stock.
Moderna, Inc. reports developments in mRNA medicines, including commercial vaccines, investigational respiratory vaccines, oncology programs and rare-disease candidates. News commonly covers regulatory authorizations and agency interactions for products such as Spikevax, mRESVIA, mNEXSPIKE and mCOMBRIAX, as well as clinical data for seasonal influenza, pandemic influenza and cancer immunotherapy programs including intismeran autogene and mRNA-4359.
Company updates also include quarterly financial results, revenue mix, expense actions, strategic partnerships, scientific meeting presentations and intellectual-property matters tied to Moderna's infectious disease portfolio and broader mRNA technology platform.
Moderna (Nasdaq: MRNA) announced the second interim analysis of its Phase 1 study for mRNA-1273, a COVID-19 vaccine. The study involved 40 healthy adults, with two doses (25 µg and 100 µg) evaluated. Results showed both doses were well-tolerated, with the 100 µg dose eliciting stronger immune responses. Notably, binding and neutralizing antibody levels were comparable between older adults and younger cohorts. The U.S. government has purchased 100 million doses with an option for 400 million more, indicating strong market potential for Moderna's vaccine.
Moderna (Nasdaq: MRNA) announced that Dr. Stephen Hoge, President, will speak at the Chardan Virtual 4th Annual Genetic Medicines Conference on October 5, 2020, at 2:00 p.m. ET. A live webcast of the event will be available in the Investors section of Moderna's website, with a replay accessible for 30 days afterward. Moderna is focused on advancing mRNA science for transformative medicines addressing various diseases and has collaborations with major organizations like AstraZeneca and Merck.